C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.51 AUD Market Closed
Market Cap: 167.8m AUD
Have any thoughts about
Cyclopharm Ltd?
Write Note

Cyclopharm Ltd
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cyclopharm Ltd
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
C
Cyclopharm Ltd
ASX:CYC
Other Current Liabilities
AU$3.7m
CAGR 3-Years
40%
CAGR 5-Years
30%
CAGR 10-Years
13%
R
Respiri Ltd
ASX:RSH
Other Current Liabilities
AU$1.2m
CAGR 3-Years
93%
CAGR 5-Years
149%
CAGR 10-Years
N/A
ImpediMed Ltd
ASX:IPD
Other Current Liabilities
AU$1.6m
CAGR 3-Years
-36%
CAGR 5-Years
-18%
CAGR 10-Years
16%
Cochlear Ltd
ASX:COH
Other Current Liabilities
AU$136.2m
CAGR 3-Years
20%
CAGR 5-Years
2%
CAGR 10-Years
9%
Optiscan Imaging Ltd
ASX:OIL
Other Current Liabilities
AU$493.3k
CAGR 3-Years
17%
CAGR 5-Years
17%
CAGR 10-Years
9%
EMvision Medical Devices Ltd
ASX:EMV
Other Current Liabilities
AU$1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cyclopharm Ltd
Glance View

Market Cap
167.8m AUD
Industry
Health Care

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

CYC Intrinsic Value
2.04 AUD
Undervaluation 26%
Intrinsic Value
Price
C

See Also

What is Cyclopharm Ltd's Other Current Liabilities?
Other Current Liabilities
3.7m AUD

Based on the financial report for Jun 30, 2024, Cyclopharm Ltd's Other Current Liabilities amounts to 3.7m AUD.

What is Cyclopharm Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
13%

Over the last year, the Other Current Liabilities growth was 113%. The average annual Other Current Liabilities growth rates for Cyclopharm Ltd have been 40% over the past three years , 30% over the past five years , and 13% over the past ten years .

Back to Top